CRMD

Cormedix Stock Analysis

AI Rating

Good
  • Quality9/10
  • Growth↑ 9/10
  • Momentum↓ 1/10
Cormedix sales and earnings growth
CRMD Growth
Great
  • Revenue Y/Y↑ 1647.67%
  • EPS Y/Y↑ 380.25%
  • FCF Y/Y↑ 232.54%
Cormedix gross and profit margin trends
CRMD Profitability
Great
  • Gross margin ↑ 92.60%
  • EPS margin↑ 75.80%
  • ROIC↑ 93.70%
Cormedix net debt vs free cash flow
CRMD Risk
Great
  • Debt / Equity↓ 0.4
  • Debt / FCF↓ 1.3
  • Interest coverage↑ 110.8

Cormedix stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗